64 related articles for article (PubMed ID: 22554429)
21. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
[TBL] [Abstract][Full Text] [Related]
22. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
[TBL] [Abstract][Full Text] [Related]
23. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study.
Ward A; Ishak K; Proskorovsky I; Caro J
Clin Ther; 2006 Nov; 28(11):1912-21. PubMed ID: 17213012
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004.
Wolfsperger M; Greil W; Rössler W; Grohmann R
J Affect Disord; 2007 Apr; 99(1-3):9-17. PubMed ID: 16989907
[TBL] [Abstract][Full Text] [Related]
25. Safety monitoring of patients on atypical antipsychotics.
Peh AL
Qual Saf Health Care; 2008 Dec; 17(6):469-72. PubMed ID: 19064665
[TBL] [Abstract][Full Text] [Related]
26. Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication.
Weissman E; Jackson C; Schooler N; Goetz R; Essock S
Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):201-7. PubMed ID: 22182457
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.
Morrato EH; Newcomer JW; Allen RR; Valuck RJ
J Clin Psychiatry; 2008 Feb; 69(2):316-22. PubMed ID: 18251625
[TBL] [Abstract][Full Text] [Related]
28. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
29. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
30. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.
Weissman EM; Zhu CW; Schooler NR; Goetz RR; Essock SM
J Clin Psychiatry; 2006 Sep; 67(9):1323-6. PubMed ID: 17017817
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of Recommended Metabolic Laboratory Parameters Among Medicaid Recipients on Second-Generation Antipsychotics in Federally Qualified Health Centers.
Uzal NE; Chavez B; Kosirog ER; Billups SJ; Saseen JJ
Ann Pharmacother; 2018 Feb; 52(2):160-165. PubMed ID: 28884591
[TBL] [Abstract][Full Text] [Related]
32. Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics.
Edelsohn GA; Parthasarathy M; Terhorst L; Karpov IO; Schuster J
J Manag Care Spec Pharm; 2015 Sep; 21(9):769-77, 777a-777cc. PubMed ID: 26308224
[TBL] [Abstract][Full Text] [Related]
33. Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics.
Rodday AM; Parsons SK; Mankiw C; Correll CU; Robb AS; Zima BT; Saunders TS; Leslie LK
J Child Adolesc Psychopharmacol; 2015 May; 25(4):351-61. PubMed ID: 25918843
[TBL] [Abstract][Full Text] [Related]
34. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.
Morrato EH; Newcomer JW; Kamat S; Baser O; Harnett J; Cuffel B
Diabetes Care; 2009 Jun; 32(6):1037-42. PubMed ID: 19244091
[TBL] [Abstract][Full Text] [Related]
35. Lipid effects of psychiatric medications.
Watanabe J; Suzuki Y; Someya T
Curr Atheroscler Rep; 2013 Jan; 15(1):292. PubMed ID: 23225174
[TBL] [Abstract][Full Text] [Related]
36. Metabolic monitoring of pediatric patients prescribed second-generation antipsychotic medication.
Roebuck JH
J Child Adolesc Psychiatr Nurs; 2024 Feb; 37(1):e12438. PubMed ID: 37586850
[TBL] [Abstract][Full Text] [Related]
37. Cardiometabolic screening and monitoring in patients prescribed antipsychotic drugs in primary care: A population-based cohort study.
Azfr Ali R; Jalal Z; Chandan JS; Subramanian A; Adderley NJ; Nirantharakumar K; Gokhale KM; Paudyal V
Compr Psychiatry; 2023 Nov; 127():152419. PubMed ID: 37717342
[TBL] [Abstract][Full Text] [Related]
38. Adherence to the monitoring of metabolic syndrome in patients receiving antipsychotics in outpatient clinics in Saudi Arabia.
Al-Awad FA; Almutairi HA; Almutairi SA; Alessa OS; Alanazi SF; Alzain NM; Albakr DM; Alzahrani SI
J Family Community Med; 2024; 31(1):42-47. PubMed ID: 38406217
[TBL] [Abstract][Full Text] [Related]
39. Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database.
Bulteau S; Le Pierres M; Artarit P; Forestier B; Michaud E; Chaslerie A; Bonnot O; Victorri-Vigneau C
Expert Opin Drug Saf; 2021 Feb; 20(2):225-233. PubMed ID: 33225754
[No Abstract] [Full Text] [Related]
40. Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting.
Ghate SR; Porucznik CA; Said Q; Hashibe M; Joy E; Brixner DI
Ment Health Fam Med; 2012 Sep; 9(3):137-48. PubMed ID: 23997820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
